title: Effect of atorvastatin on plasma NT-proBNP and inflammatory cytokine expression in patients with heart failure.
abstract: The aim of this study was to explore the effect of atorvastatin intervention on plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) and inflammatory cytokine levels in patients with heart failure (HF). One hundred and twenty-three HF patients were selected from our hospital and randomly divided into control (N = 61) and observation (N = 62) groups; the former received conventional treatment, while the latter were given conventional treatment combined with atorvastatin. Plasma NT-proBNP, inflammatory cytokines [high-sensitive C-reactive protein (hs-CRP), interleukin (IL)-6, IL-10] and cardiac function [left ventricular end-diastolic dimension (LVEDD), left ventricular ejection fraction (LVEF), end-diastolic maximum flow rate ratio (E/A)] were compared among groups. The effective rate of treating HF significantly increased after atorvastatin treatment. The plasma NT-proBNP, IL-6, IL-10, hs-CRP, and LVEDD levels significantly decreased (P < 0.05), while the LVEF and E/A levels significantly increased (P < 0.05) in the observation group compared to the control group and before intervention. The NT-proBNP and cytokine levels significantly differed among patients with different classes of heart function (P < 0.05); the NT-proBNP and cytokine levels increased with the severity of heart function. Pearson's correlation analysis revealed a negative correlation between the NT-proBNP and inflammatory cytokine levels and LVEF and E/A values, and a positive correlation between these factors and LVEDD (P < 0.05). In conclusion, atorvastatin significantly improves cardiac function; the mechanism atorvastatin action was related to the decrease in plasma NT-proBNP and inflammatory cytokine levels.
authors.affiliation: Department of Cardiovascular Medicine, Henan Provincial People's Hospital, Zhengzhou, China.
authors.forename: H Y
authors.initials: HY
authors.lastname: Duan
authors.affiliation: Department of Cardiovascular Medicine, Henan Provincial People's Hospital, Zhengzhou, China.
authors.forename: D M
authors.initials: DM
authors.lastname: Liu
authors.affiliation: Department of Cardiovascular Medicine, Henan Provincial People's Hospital, Zhengzhou, China.
authors.forename: P
authors.initials: P
authors.lastname: Qian
authors.affiliation: Department of Cardiovascular Medicine, Henan Provincial People's Hospital, Zhengzhou, China.
authors.forename: S L
authors.initials: SL
authors.lastname: Wang
authors.affiliation: Department of Cardiovascular Medicine, Henan Provincial People's Hospital, Zhengzhou, China.
authors.forename: L J
authors.initials: LJ
authors.lastname: Yan
authors.affiliation: Department of Cardiovascular Medicine, Henan Provincial People's Hospital, Zhengzhou, China.
authors.forename: J T
authors.initials: JT
authors.lastname: Wu
authors.affiliation: Department of Cardiovascular Medicine, Henan Provincial People's Hospital, Zhengzhou, China.
authors.forename: H T
authors.initials: HT
authors.lastname: Yang
authors.affiliation: Department of Cardiovascular Medicine, Henan Provincial People's Hospital, Zhengzhou, China.
authors.forename: X W
authors.initials: XW
authors.lastname: Fan
authors.affiliation: Department of Cardiovascular Medicine, Henan Provincial People's Hospital, Zhengzhou, China.
authors.forename: Y J
authors.initials: YJ
authors.lastname: Chu
mesh_terms: D000328:Adult; D000368:Aged; D000069059:Atorvastatin / Q000627:therapeutic use*; D015415:Biomarkers; D016022:Case-Control Studies; D016207:Cytokines / Q000097:blood*; D004452:Echocardiography; D005260:Female; D006333:Heart Failure / Q000097:blood* / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D006334:Heart Function Tests; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D018836:Inflammation Mediators / Q000097:blood*; D008297:Male; D008875:Middle Aged; D020097:Natriuretic Peptide, Brain / Q000097:blood*; D010446:Peptide Fragments / Q000097:blood*; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D016207:Cytokines; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D018836:Inflammation Mediators; D010446:Peptide Fragments; C109794:pro-brain natriuretic peptide (1-76); D020097:Natriuretic Peptide, Brain; D000069059:Atorvastatin